Evidence map›Paper›PMID 41186665›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026

Turbitest: an innovative rapid test for determining in vitro susceptibility to ceftazidime-avibactam plus aztreonam in Enterobacterales.

Natália Kehl Moreira, Gabriela da Silva Collar, Júlia Cover Salvador, Mariana Preussler Mott, Ramon Marx, Patricia Orlandi Barth, Afonso Luís Barth, Juliana Caierão

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Natália Kehl MoreiraLaboratório de Pesquisa em Bacteriologia Clínica (LaBaC), Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. natkehl@hotmail.com.
Gabriela da Silva CollarLaboratório de Pesquisa em Bacteriologia Clínica (LaBaC), Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Júlia Cover SalvadorLaboratório de Pesquisa em Bacteriologia Clínica (LaBaC), Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Mariana Preussler MottUnidade de Microbiologia, Serviço de Diagnóstico Laboratorial, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Ramon MarxLaboratório Central de Análises Clínicas, Grupo Hospitalar Conceição, Porto Alegre, Brazil.
Patricia Orlandi BarthLaboratório de Pesquisa em Resistência Bacteriana (LABRESIS), Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Afonso Luís BarthLaboratório de Pesquisa em Resistência Bacteriana (LABRESIS), Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Juliana CaierãoLaboratório de Pesquisa em Bacteriologia Clínica (LaBaC), Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico INPRA; INCT/MCT/CNPq/CAPES/FAPs n.197 - 16/2014
6 · The paper itself

Abstract

Treating carbapenem-resistant Enterobacterales, mainly those producing metallo-β-lactamases (MBL) is a subject of major concern. The combination aztreonam-avibactam (AZA) was developed in an attempt to overcome this challenge, as avibactam inhibits KPC and other serine-β-lactamases, enabling aztreonam (ATM) to act against MBL. However, in scenarios where AZA is not licensed so far, the combination of ATM with ceftazidime-avibactam (CZA) is an alternative that has been proved in vivo efficacy and in vitro synergic activity. We propose the TurbiTest, an alternative method based on turbidity measurement of bacterial growth after a short incubation period (4 h) in the presence and absence of antibiotics to easily determine susceptibility to this combination. A total of 134 Enterobacterales harboring a variety of resistance genes (52 bla

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsAztreonamCeftazidimeEnterobacteriaceaebeta-LactamasesDrug CombinationsDrug Resistance, Multiple, BacterialEnterobacteriaceae InfectionsHumansMicrobial Sensitivity TestsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsAztreonambeta-LactamasesCeftazidimeDrug CombinationsAztreonam-avibactamCeftazidime-avibactamTurbidity

Identifiers

PMID41186665

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.